Brainstorm cell therapeutics and fda agree to potential nurown regulatory pathway for approval in als

Brainstorm cell therapeutics and fda agree to potential nurown® regulatory pathway for approval in als.brainstorm cell therapeutics - fda confirmed fully enrolled phase 3 als trial is collecting relevant data critical to assessment of nurown efficacy.brainstorm cell therapeutics inc - fda indicated they will look at "totality of evidence" in expected phase 3 clinical trial data.
BCLI Ratings Summary
BCLI Quant Ranking